Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BetterLife Pharma ( (TSE:BETR) ) has shared an update.
BetterLife Pharma has highlighted the advantages of its proprietary compound BETR-001, which remains non-hallucinogenic even at high doses, unlike traditional LSD microdosing. The company plans to file an IND and begin human clinical trials by the second half of 2026, targeting conditions such as traumatic brain injury, cluster headaches, and migraines. BETR-001’s ability to be administered at full doses without hallucinations positions it as a promising treatment for a range of psychiatric disorders, potentially enhancing BetterLife’s market position in the biotech industry.
Spark’s Take on TSE:BETR Stock
According to Spark, TipRanks’ AI Analyst, TSE:BETR is a Underperform.
BetterLife Pharma is currently in a precarious financial position with no revenue, substantial losses, and a high leverage risk due to negative equity. Technical indicators show a lack of momentum, and the valuation is unattractive due to negative earnings. The overall outlook is negative, reflecting significant financial instability.
To see Spark’s full report on TSE:BETR stock, click here.
More about BetterLife Pharma
BetterLife Pharma Inc. is an emerging biotechnology company focused on developing and commercializing BETR-001, a non-hallucinogenic derivative of LSD, for the treatment of various neurological disorders. The company is also exploring strategic alternatives for a drug candidate aimed at treating viral infections.
Average Trading Volume: 127,305
Technical Sentiment Signal: Sell
Current Market Cap: C$9.87M
For a thorough assessment of BETR stock, go to TipRanks’ Stock Analysis page.